SARS-CoV

亜型選択性的な製品

SARS-CoV-2

SARS-CoV製品

All (22)
SARS-CoV阻害剤 (18)
SARS-CoV抗体(3)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1386	Nafamostat mesilate (FUT-175)	Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis.	J Immunother Cancer, 2024, 12(11)e009805 Cell Death Dis, 2024, 15(2):109 CNS Neurosci Ther, 2024, 30(6):e14822
S8969	Molnupiravir (EIDD-2801)	Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N⁴-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.	Antiviral Res, 2024, 225:105840 Front Pharmacol, 2024, 15:1431617 BMC Complement Med Ther, 2024, 24(1):274
S9866	Nirmatrelvir (PF-07321332)	Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (M^pro, also referred to as 3CL protease) with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme.	Antiviral Res, 2024, 225:105840 J Biol Chem, 2024, S0021-9258(24)02176-8 Viruses, 2024, 16(7)1158
S0833	EIDD-1931 (NHC)	EIDD-1931 (NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir.	Nucleic Acids Res, 2023, 10.1093/nar/gkad1002 NPJ Digit Med, 2022, 5(1):83 J Med Virol, 2022, 10.1002/jmv.27650
S9731	PF-00835231	PF-00835231 is a 3CL^pro (M^pro) inhibitor that may targets SARS-CoV-2 protease 3CL^pro as a potential new treatment for COVID-19.	Mol Cell, 2022, S1097-2765(22)00433-6 Bioorg Med Chem Lett, 2022, 66:128732 Nat Commun, 2021, 12(1):6786
S0515	PLpro inhibitor	PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor with IC50 of 2.6 μM.	PLoS Pathog, 2023, 19(8):e1011592 PLoS Pathog, 2023, 19(8):e1011592 bioRxiv, 2022, 2022.08.06.503039
A2403	Narsoplimab (Anti-MASP2)	Narsoplimab (Anti-MASP2) is a monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. MW: 145.5 kD.
A2853	Gimsilumab (Anti-CSF2 / GM-CSF)	Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD.
A2854	Lenzilumab (Anti-CSF2 / GM-CSF)	Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD.
E1900^New	Simnotrelvir	Simnotrelvir(SIM0417, SARS-CoV-2-IN-41) is an inhibitor of coronavirus main proteinase (3CLpro) (SARS-CoV-2 3CLpro) with an IC50 of 24 nM. It has a potential anti-SARS-CoV-2 activity.
S0793	ML188	ML188 is a non-covalent SARS-CoV 3CLpro inhibitor with IC50 of 1.5 μM. ML188 has antiviral activity.
S0875	XP-59	XP-59 is a potent inhibitor of the SARS-CoV M^pro, with a Ki of 0.1 μM.
S6845	GRL0617	GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. GRL0617 inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.	J Virol, 2024, e0085524.
E1112	GS-621763	GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM.
E0613	TC-067533	TC-067533 is a potent SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 of 8.7 μM.
S3553	Riamilovir	Riamilovir (Triazavirin) is a broad-spectrum antiviral drug candidate, which can be used for potential application against the Coronavirus 2019-nCoV.
E1111	VV116	VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
E0052	Merafloxacin	Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses.
E1131	Ensitrelvir fumarate	S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM.
S9963	paquinimod	Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.	Cell Rep, 2024, 43(11):114900
E1174	Coronastat(NK01-63)	Coronastat(NK01-63) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.
E1013	Bemnifosbuvir Hemisulfate (AT-527)	Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511. AT-511 is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.
S1386	Nafamostat mesilate (FUT-175)	Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis.	J Immunother Cancer, 2024, 12(11)e009805 Cell Death Dis, 2024, 15(2):109 CNS Neurosci Ther, 2024, 30(6):e14822
S8969	Molnupiravir (EIDD-2801)	Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N⁴-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.	Antiviral Res, 2024, 225:105840 Front Pharmacol, 2024, 15:1431617 BMC Complement Med Ther, 2024, 24(1):274
S9866	Nirmatrelvir (PF-07321332)	Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (M^pro, also referred to as 3CL protease) with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme.	Antiviral Res, 2024, 225:105840 J Biol Chem, 2024, S0021-9258(24)02176-8 Viruses, 2024, 16(7)1158
S0833	EIDD-1931 (NHC)	EIDD-1931 (NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir.	Nucleic Acids Res, 2023, 10.1093/nar/gkad1002 NPJ Digit Med, 2022, 5(1):83 J Med Virol, 2022, 10.1002/jmv.27650
S9731	PF-00835231	PF-00835231 is a 3CL^pro (M^pro) inhibitor that may targets SARS-CoV-2 protease 3CL^pro as a potential new treatment for COVID-19.	Mol Cell, 2022, S1097-2765(22)00433-6 Bioorg Med Chem Lett, 2022, 66:128732 Nat Commun, 2021, 12(1):6786
S0515	PLpro inhibitor	PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor with IC50 of 2.6 μM.	PLoS Pathog, 2023, 19(8):e1011592 PLoS Pathog, 2023, 19(8):e1011592 bioRxiv, 2022, 2022.08.06.503039
E1900^New	Simnotrelvir	Simnotrelvir(SIM0417, SARS-CoV-2-IN-41) is an inhibitor of coronavirus main proteinase (3CLpro) (SARS-CoV-2 3CLpro) with an IC50 of 24 nM. It has a potential anti-SARS-CoV-2 activity.
S0793	ML188	ML188 is a non-covalent SARS-CoV 3CLpro inhibitor with IC50 of 1.5 μM. ML188 has antiviral activity.
S0875	XP-59	XP-59 is a potent inhibitor of the SARS-CoV M^pro, with a Ki of 0.1 μM.
S6845	GRL0617	GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. GRL0617 inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.	J Virol, 2024, e0085524.
E1112	GS-621763	GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM.
E0613	TC-067533	TC-067533 is a potent SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 of 8.7 μM.
E1111	VV116	VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
E0052	Merafloxacin	Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses.
E1131	Ensitrelvir fumarate	S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM.
S9963	paquinimod	Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.	Cell Rep, 2024, 43(11):114900
E1174	Coronastat(NK01-63)	Coronastat(NK01-63) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.
E1013	Bemnifosbuvir Hemisulfate (AT-527)	Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511. AT-511 is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.
A2403	Narsoplimab (Anti-MASP2)	Narsoplimab (Anti-MASP2) is a monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. MW: 145.5 kD.
A2853	Gimsilumab (Anti-CSF2 / GM-CSF)	Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD.
A2854	Lenzilumab (Anti-CSF2 / GM-CSF)	Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD.
E1900^New	Simnotrelvir	Simnotrelvir(SIM0417, SARS-CoV-2-IN-41) is an inhibitor of coronavirus main proteinase (3CLpro) (SARS-CoV-2 3CLpro) with an IC50 of 24 nM. It has a potential anti-SARS-CoV-2 activity.

SARS-CoV阻害剤の選択性比較